Bortezomib
- Generic Name
- Bortezomib
- Brand Names
- Velcade, Bortezomib Accord, Bortezomib Hospira, Bortezomib Fresenius Kabi, Bortezomib Sun
- Drug Type
- Small Molecule
- Chemical Formula
- C19H25BN4O4
- CAS Number
- 179324-69-7
- Unique Ingredient Identifier
- 69G8BD63PP
- Background
Bortezomib is a dipeptide boronic acid derivative and proteasome inhibitor used to treat multiple myeloma and mantle cell lymphoma. The 26S proteasome is a protein complex that degrades ubiquitinated proteins in the ubiquitin-proteasome pathway: reversible inhibition of the 26S proteasome, leading to cell cycle arrest and apoptosis of cancer cells, is though...
- Indication
Bortezomib is indicated for the treatment of adults with multiple myeloma or mantle cell lymphoma.
- Associated Conditions
- Mantle Cell Lymphoma (MCL), Multiple Myeloma (MM)
- Associated Therapies
- -
An Exploratory Clinical Study on Bortezomib for the Treatment of Refractory Rheumatoid Arthritis
- First Posted Date
- 2024-01-22
- Last Posted Date
- 2024-01-22
- Lead Sponsor
- Peking Union Medical College Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT06215638
- Locations
- 🇨🇳
Peking Union Medical Cllege Hospital, Beijing, Beijing, China
A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide
- Conditions
- Interventions
- First Posted Date
- 2024-01-17
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 795
- Registration Number
- NCT06208150
- Locations
- 🇨🇳
The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China
🇨🇳Tongji Hospital, Tongji Medical College of HUST, Wuhan, China
🇮🇱Carmel Medical Center, Haifa, Israel
A Clinical Study on the Whole-course Management (BCD-KPD-AutoHSCT) Scheme for Patients With RIMM
- First Posted Date
- 2024-01-12
- Last Posted Date
- 2024-01-12
- Lead Sponsor
- Peking University First Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT06203145
- Locations
- 🇨🇳
Peking University First Hospital, Beijing, Beijing, China
Optimize First-line Treatment for AL Amyloidosis With t (11; 14)
- Conditions
- Interventions
- First Posted Date
- 2024-01-05
- Last Posted Date
- 2024-02-06
- Lead Sponsor
- Jin Lu, MD
- Target Recruit Count
- 41
- Registration Number
- NCT06192979
- Locations
- 🇨🇳
Peking University People's Hospital, Beijing, Beijing, China
Phase 2 Study Applying MRD Techniques for Participants With Previously Untreated Multiple Myeloma Treated With D-VRd Prior To and After High-dose Therapy Followed by ASCT - TAURUS
- Conditions
- Interventions
- First Posted Date
- 2024-01-05
- Last Posted Date
- 2024-04-23
- Lead Sponsor
- Stichting European Myeloma Network
- Target Recruit Count
- 200
- Registration Number
- NCT06189833
- Locations
- 🇬🇷
St Savvas Cancer Hospital, Athens, Greece
🇩🇪Universitätsklinikum Hamburg - Eppendorf, Hamburg, Germany
🇦🇹Innsbruck Medical University, Innsbruck, Austria
Comparing the Combination of Selinexor-Daratumumab-Velcade-Dexamethasone (Dara-SVD) With the Usual Treatment (Dara-RVD) for High-Risk Newly Diagnosed Multiple Myeloma
- Conditions
- Interventions
- Procedure: Biospecimen CollectionProcedure: Bone Marrow AspirationProcedure: Bone Marrow BiopsyDrug: BortezomibProcedure: Computed TomographyBiological: DaratumumabDrug: Daratumumab and Recombinant Human HyaluronidaseDrug: DexamethasoneDrug: LenalidomideProcedure: Magnetic Resonance ImagingProcedure: Positron Emission TomographyDrug: Selinexor
- First Posted Date
- 2023-12-13
- Last Posted Date
- 2024-10-23
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 70
- Registration Number
- NCT06169215
- Locations
- 🇺🇸
University of California Davis Comprehensive Cancer Center, Sacramento, California, United States
🇺🇸Smilow Cancer Center/Yale-New Haven Hospital, New Haven, Connecticut, United States
🇺🇸UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine, California, United States
Study Assessing Activity of Intravenous (IV) ABBV-383 Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2023-12-06
- Last Posted Date
- 2024-11-04
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 380
- Registration Number
- NCT06158841
- Locations
- 🇨🇳
The First Affiliated Hospital, Zhejiang University School of Medicine /ID# 260883, Hangzhou, Zhejiang, China
🇺🇸Alta Bates Summit Medical Center for Research /ID# 261438, Berkeley, California, United States
🇺🇸Providence - St. Jude Medical Center /ID# 262031, Fullerton, California, United States
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
- Conditions
- Interventions
- First Posted Date
- 2023-11-30
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 492
- Registration Number
- NCT06152575
- Locations
- 🇺🇸
Community Health Network, Inc., Indianapolis, Indiana, United States
🇺🇸Cayuga Cancer Center at Cayuga Park, Ithaca, New York, United States
🇺🇸Cayuga Medical Center, Ithaca, New York, United States
Study to Evaluate the Safety and Efficacy of Daratumumab and Carfilzomib-based Induction/Consolidation/Maintenance Therapy in Transplant-eligible, Ultra High-risk, Newly Diagnosed Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2023-11-21
- Last Posted Date
- 2024-01-03
- Lead Sponsor
- Wuhan Union Hospital, China
- Target Recruit Count
- 54
- Registration Number
- NCT06140966
- Locations
- 🇨🇳
Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
A Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab in People With Monoclonal Gammopathy of Renal Significance (MGRS)
- Conditions
- Interventions
- First Posted Date
- 2023-10-16
- Last Posted Date
- 2024-07-30
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 53
- Registration Number
- NCT06083922
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center Suffolk - Commack (Limited Protocol Activities), Commack, New York, United States
🇺🇸Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison, New York, United States
🇺🇸Memorial Sloan Kettering Nassau (Limited Protocol Activities), Uniondale, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.